DOCSLIB.ORG

CP-70429, a New Penem Antibiotic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CP-70429, a New Penem Antibiotic ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1993, P. 1547-1551 Vol. 37, No. 7 0066-4804/93/071547-05$02.00/0 Copyright © 1993, American Society for Microbiology In Vitro Antibacterial Activity and ,-Lactamase Stability of CP-70,429, a New Penem Antibiotic MASASHI MINAMIMURA, YUMI TANIYAMA, EIKO INOUE,* AND SUSUMU MITSUHASHI Episome Institute, 2220 Kogure, Fujimi-mura, Seta-gun, Gunma, Japan Received 14 January 1993/Accepted 15 April 1993 In in vitro susceptibility tests, the new penem CP-70,429 showed potent antibacterial activity against gram-positive and gram-negative bacteria except Pseudomonas aeruginosa and Xanthomonas maltophilia. CP-70,429 was stable to various types of 13-lactamases except for the enzyme from X. maltophilia and was 16- to 128-fold more active than the other compounds against 13-lactamase-producing strains of Enterobacter cloacae and Citrobacterfreundii. In the past several years, many 1-lactam antibiotics with cus aureus, like the other agents against which CP-70,429 broad antibacterial activities have undergone clinical trials. was compared. CP-70,429 showed potent activity against The penem antibiotics FCE22101 and SY5555 have broad streptococci, as did the other compounds tested. Against antimicrobial spectra and high levels of stability to ,B-lacta- Enterococcus faecalis, CP-70,429 was 4- to 16-fold more mases (4, 9). The in vitro activity of CP-65,207 was previ- active than the cephems tested, on the basis of the MIC90s. ously reported by Gootz et al. (3); CP-65,207 is a mixture of CP-70,429 was the most active compound against Esche- stereoisomers of the optically pure CP-70,429. CP-70,429 is a richia coli, Kebsiella pneumoniae, Morganella morganii, new penem antibiotic, which is stable to renal dehydropep- and Providencia rettgeni. Its activity was 4- to 16-fold greater tidase I (2, 8). We report here the in vitro antibacterial than those of the other penems and 2- to 8-fold greater than activity of CP-70,429 and its stability to various types of those of the cephems. The MIC90s of CP-70,429 were 0.39 P-lactamases. The following antibacterial agents were used: and 0.78 jig/ml for Citrobacter freundii and Enterobacter CP-70,429, Pfizer Pharmaceuticals Inc., Tokyo, Japan; cloacae, respectively; these two strains were resistant to FCE22101, Farmitalia Carlo Erba Co., Ltd., Tokyo, Japan; ceftazidime and cefuzonam. Its activity was 8- to 16-fold SY5555, Suntory Co., Ltd., Tokyo, Japan; ceftazidime, greater than those of the other penems. Nihon Glaxo Co., Ltd., Tokyo, Japan; and cefuzonam, CP-70,429 had poor activity against Serratia marcescens, Lederle Japan Co., Ltd., Tokyo, Japan. The clinical isolates as did the other compounds tested. CP-70,429, like ceftazi- of bacteria used in the present study were collected from dime, was four- to eightfold more active than the other several hospitals in Japan from 1984 to 1990. The 3-lacta- penems and cefuzonam against the Proteus group of organ- were from mase-producing strains tested selected stock isms. CP-70,429 was four- to eightfold more active than the were determined by cultures in our laboratory (1, 7). MICs other penems against Haemophilus influenzae. At a concen- the twofold agar dilution method by using Sensitivity Disk of 0.10 CP-70,429 inhibited all Neisseria unless other- tration j.g/ml, Agar (Nissui Pharmaceutical, Tokyo, Japan), gonorrhoeae and Branhamella catarrhalis isolates tested, as wise The final cell inoculum was approximately specified (5). did ceftazidime. CP-70,429 was inactive against Pseudo- 104 CFU per spot. monas aeruginosa, as were the other penems tested and The various types of ,-lactamases used in the present cefuzonam. CP-70,429 was inactive against Xanthomonas study were totally or partially purified by the methods maltophilia, as were the other compounds tested. and were stored at -80°C (6). The reported previously The antibacterial activity of CP-70,429 against 3-lacta- stability of the antibiotics to was measured by a P-lactamase mase-producing strains of various species was tested. CP- spectrophotometric assay (10). tested The MICs of CP-70,429 and the other agents for 1,555 70,429 showed potent activity against the organisms except for Pseudomonas aeruginosa and Xanthomonas mal- clinical isolates are summarized in Table 1. CP-70,429 had a In CP-70,429 was 16- to 128- broad spectrum of antibacterial activity and was highly tophilia (Table 2). particular, fold more active than the comparison compounds against active against gram-positive and gram-negative bacteria, and particularly members of the family Enterobacteraceae. In P-lactamase-producing strains of Enterobacter cloacae was more active than ceftazidime against Citrobacterffreundii. general, CP-70,429 to hydrolysis gram-positive cocci. The MIC of CP-70,429 for 90% of The susceptibility of CP-70,429 enzymatic was tested with various types of ,B-lactamases. Hydrolysis of isolates tested which was similar to those of (MIC0), the tested was expressed as the relative rate of and SY5555, was 0.10 p.g/ml for methicillin- compounds FCE22101 hydrolysis normalized with respect to the rate of hydrolysis susceptible Staphylococcus aureus. In contrast, CP-70,429 of cephaloridine or penicillin G, which was set at 100 (Table poor activity against methicillin-resistant Staphylococ- had 3). CP-70,429 was stable to various types of 3-lactamases but was hydrolyzed by Xanthomonas maltophilia oxyimi- nocephalosporinase type II, that is, type 3 of the classifica- * Corresponding author. tion of Bush (1), as were the comparison compounds. The 1547 1548 NOTES ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. Antibacterial activity of CP-70,429 against clinical isolates MIC (jg/rMI)a Organism (no. of isolates) Antibiotic Range 50% 90% Staphylococcus aureus, methicillin susceptible (75) CP-70,429 0.05-0.10 0.10 0.10 FCE22101 0.10-0.20 0.10 0.10 SY5555 0.10-0.20 0.20 0.20 Ceftazidime 3.13-12.5 6.25 6.25 Cefuzonam 0.20-0.78 0.39 0.39 Staphylococcus aureus, methicillin resistant (97) CP-70,429 0.39->100 12.5 100 FCE22101 0.20-> 100 1.56 100 SY5555 0.39-> 100 12.5 >100 Ceftazidime 12.5->100 >100 >100 Cefuzonam 0.39-> 100 50 100 Streptococcus pneumoniae (50) CP-70,429 C0.006-0.78 .0.006 0.10 FCE22101 C0.006-1.56 0.025 0.20 SY5555 <0.006-0.39 S0.006 0.05 Ceftazidime 0.025-0.78 0.10 0.39 Cefuzonam C0.006-0.39 .0.006 0.10 Streptococcus pyogenes (92) CP.70,429 <0.006-0.025 0.012 0.025 FCE22101 C0.006-0.10 0.05 0.05 SY5555 <0.006-0.025 0.012 0.025 Ceftazidime 0.025-0.20 0.10 0.10 Cefuzonam <0.006-0.10 50.006 0.012 Enterococcus faecalis (104) CP-70,429 0.78-50 3.13 6.25 FCE22101 1.56-12.5 1.56 3.13 SY5555 0.39-6.25 0.78 1.56 Ceftazidime 12.5->100 50 >100 Cefuzonam 0.39-> 100 1.56 25 Escherichia coli (100) CP-70,429 0.012-0.20 0.025 0.05 FCE22101 0.39-0.78 0.39 0.78 SY5555 0.10-3.13 0.78 0.78 Ceftazidime 0.012-1.56 0.20 0.39 Cefuzonam 0.025-0.78 0.10 0.20 Klebsiella pneumoniae (123) CP-70,429 0.025-0.10 0.025 0.05 FCE22101 0.39-0.78 0.78 0.78 SY5555 0.20-25 0.39 0.78 Ceftazidime 0.025-12.5 0.10 0.39 Cefuzonam 0.025-0.78 0.10 0.20 Klebsiella oxytoca (100) CP-70,429 0.025-0.39 0.05 0.10 FCE22101 0.20-6.25 0.78 0.78 SY5555 0.10-3.13 0.39 1.56 Ceftazidime .0.006-0.39 0.05 0.10 Cefuzonam 50.006-0.39 0.05 0.10 Citrobacterfreundii (96) CP-70,429 0.025-3.13 0.10 0.39 FCE22101 0.78-50 3.13 6.25 SY5555 0.39-25 1.56 6.25 Ceftazidime 0.05-> 100 0.78 >100 Cefuzonam 0.10->100 0.39 50 Enterobacter cloacae (100) CP-70,429 0.012-1.56 0.20 0.78 FCE22101 0.78-25 3.13 6.25 SY5555 0.39-12.5 3.13 6.25 Ceftazidime 0.05->100 0.39 100 Cefuzonam 0.05->100 0.39 50 Serratia marcescens (100) CP-70,429 0.05->100 0.78 50 FCE22101 1.56-> 100 6.25 50 SY5555 1.56->100 25 >100 Ceftazidime 0.10-> 100 0.78 >100 Cefuzonam 0.20-> 100 1.56 >100 Continued on followingpage VOL. 37,1993 NOTES 1549 TABLE 1-Continued MIC (p.g/ml)a Organism (no. of isolates) Antibiotic MIC (,ug/ml Range 50% 90% Morganella morganii (70) CP-70,429 0.05-1.56 0.39 0.78 FCE22101 0.78-6.25 3.13 3.13 SY5555 0.39-25 1.56 3.13 Ceftazidime 0.05->100 0.05 3.13 Cefuzonam 0.025-12.5 0.05 3.13 Providencia rettgeri (48) CP-70,429 s0.006-0.39 0.20 0.20 FCE22101 0.39-3.13 0.78 1.56 SY5555 0.10-6.25 1.56 3.13 Ceftazidime 50.006-3.13 0.10 0.39 Cefuzonam <0.006-6.25 0.05 0.78 Proteus mirabilis (101) CP-70,429 0.012-0.39 0.10 0.20 FCE22101 0.39-1.56 0.78 1.56 SY5555 0.05-6.25 0.78 3.13 Ceftazidime 0.05-1.56 0.10 0.39 Cefuzonam 0.05-1.56 0.39 0.78 Proteus vulgaris (95) CP-70,429 0.025-0.39 0.05 0.10 FCE22101 0.39-3.13 0.78 0.78 SY5555 0.20-1.56 0.39 1.56 Ceftazidime 0.05-1.56 0.10 0.20 Cefuzonam 0.025-12.5 0.39 0.78 Neisseria gonorrhoeae (21) CP-70,429 .0.006-0.10 0.025 0.05 FCE22101 .0.006-0.10 0.05 0.05 SY5555 .0.006-0.05 0.025 0.05 Ceftazidime 0.012-0.10 0.012 0.05 Cefuzonam C0.006-0.10 C0.006 0.05 Haemophilus influenzae (48) CP-70,429 0.025-0.39 0.20 0.20 FCE22101 0.10-1.56 0.20 0.78 SY5555 0.10-3.13 0.20 1.56 Ceftazidime 0.025-3.13 0.10 0.39 Cefuzonam .0.006-0.20 0.012 0.10 Branhamella catarrhalis (33) CP-70,429 .0.006-0.10 0.025 0.10 FCE22101 0.05-0.39 0.10 0.20 SY5555 0.025-0.39 0.10 0.39 Ceftazidime 0.012-0.10 0.05 0.05 Cefuzonam 0.025-0.39 0.10 0.39 Pseudomonas aeruginosa (54) CP-70,429 12.5-200 25 100 FCE22101 25->400 100 400 SY5555 50->400 >400 Ceftazidime 0.39-100 1.56 100 Cefuzonam 6.25->400 50 >400 Xanthomonas maltophilia (48) CP-70,429 3.13-> 100 100 >100 FCE22101 3.13-> 100 >100 >100 SY5555 25-> 100 >100 >100 Ceftazidime 0.39->100 50 100 Cefuzonam 0.20-> 100 25 100 a 50% and 90%, MICs for 50 and 90% of organisms tested, respectively.
Load more

Recommended publications
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Of Cephalosporins. Cefuzonam (CZON, Lederle Japan, Ltd
    1346 THE JOURNAL OF ANTIBIOTICS AUG. 1992 STRUCTURE-BINDING RELATIONSHIP AND BINDING SITES OF CEPHALOSPORINS IN HUMAN SERUM ALBUMIN Shuichi Tawara*, Satoru Matsumoto1, Yoshimi Matsumoto1, Toshiaki Kamimura^* and Sachiko GoTOn f New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-1-6 Kashima, Yodogawa-ku, Osaka 532, Japan tjDepartment of Microbiology, Toho University School of Medicine, 5-21-16 Ohmori Nishi, Ohta-ku, Tokyo 143, Japan (Received for publication January 29, 1992) The binding of some cephalosporins to human serum albumin (HSA) was studied by an ultra filtration technique. Changes in C-3 side chain resulted in marked changes in the binding to HSA,but changes in C-7 side chain did not. Cephalosporins were classified into three groups by C-3 side chain: (i) Cationic side chain with low affinity for HSA;(ii) anionic side chain with high affinity for HSA; (iii) non ionized side chain, in which binding to HSAwas dependent on lipophilicity. These findings suggest that electrostatic and hydrophobic forces play a role in the binding affinity of cephalosporins for HSA. The binding of cephalosporins with high HSAaffinity was displaced significantly by warfarin but not by phenylbutazone, L-tryptophan, or diazepam. The interaction of the cephalosporins with high affinity for HSAwith chemically modified HSAwas investigated to clarify the amino acid residues of HSAinvolved in the cephalosporin binding sites. The binding of the cephalosporins decreased remarkably with the modification of the tyrosine residues. These results suggest that the binding site of cephalosporins is located in the vicinity of warfarin binding site rather than benzodiazepine binding site and that tyrosine residues are involved in the cephalosporin binding site.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • 抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定）
    抗微生物薬略語一覧表 （Abbreviations of Antimicrobial Agents） （日本化学療法学会制定） 略 語 一般名（慣用名） 開発番号 略 語 一般名（慣用名） 開発番号 BLs ● β-ラクタム系 CEC cephacetrile （β-lactams） CEPR cephapirin PCs ペニシリン系 CER cephaloridine （penicillins） CET cephalothin ABPC ampicillin CEZ cefazolin ACPC ciclacillin CFCL cefclidin E1040 AMPC amoxicillin CFDC cefiderocol S-649266 APPC apalcillin PC-904 CFLP cefluprenam E1077 ASPC aspoxicillin TA-058 CFPM cefepime BMY-28142 BAPC bacampicillin CFS cefsulodin SCE-129 CBPC carbenicillin CFSL cefoselis FK037 CFPC carfecillin CMD cefamandole CIPC carindacillin CMX cefmenoxime SCE-1365 DMPPC methicillin CPIZ cefpimizole AC-1370 IPABPC hetacillin CPM cefpiramide SM-1652 LAPC lenampicillin KBT-1585 CPR cefpirome HR-810 MCIPC cloxacillin CPZ cefoperazone T-1551 MDIPC dicloxacillin CTM cefotiam SCE-963 MFIPC flucloxacillin CTRX ceftriaxone Ro13-9904 MPC mecillinam CTX cefotaxime MPIPC oxacillin CTZ ceftezole MZPC mezlocillin CXM cefuroxime NFPC nafcillin CZON cefuzonam L-015 PCG benzylpenicillin CZOP cefozopran SCE-2787 （penicillin G） CZX ceftizoxime PCV phenoxymethyl penicillin SBT/CPZ sulbactam/cefoperazone （penicillin V） TAZ/CTLZ tazobactam/ceftolozane MK-7625A PEPC phenethicillin （経口用） PIPC piperacillin CCL cefaclor PMPC pivmecillinam CDTR-PI cefditoren pivoxil ME-1207 PPPC propicillin CDX cefadroxil BL-S578 PVPC pivampicillin CED cefradine SBPC sulbenicillin CEG cephaloglycin SBTPC sultamicillin CEMT-PI cefetamet pivoxil Ro15-8075 TAPC talampicillin CETB ceftibuten 7432-S TIPC ticarcillin CEX cephalexin ABPC/ CFDN cefdinir FK482 MCIPC ampicillin/cloxacillin
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]
  • Supplemental Material Etable 1. Variable Classification in EHR
    Supplemental Material eTable 1. Variable classification in EHR continuity cohort vs non-EHR continuity cohort mean capture proportion <60% mean capture proportion ≥60% Variable N (%) based N (%) based Stand Sensi- N (%) based N (%) based Stand Sensi-tivity on EHR on all data diff tivity on EHR on all data diff Dementia 4147 (4) 12577 (11) 0.28 0.33 1112 (5) 1350 (7) 0.05 0.82 Atrial fibrillation 8780 (7) 22493 (19) 0.34 0.39 2079 (10) 2315 (11) 0.04 0.90 Chronic lung disease 6643 (6) 25606 (21) 0.48 0.26 2901 (14) 3407 (17) 0.07 0.85 Chronic liver disease 2183 (2) 8961 (8) 0.27 0.24 1102 (5) 1355 (7) 0.05 0.81 Chronic kidney 4565 (4) 15638 (13) 0.34 0.29 2076 (10) 2372 (12) 0.05 0.88 disease Cancer 23113 (19) 56173 (47) 0.61 0.41 7260 (35) 8087 (40) 0.08 0.90 Diabetes 8225 (7) 27351 (23) 0.46 0.30 3975 (19) 4378 (21) 0.05 0.91 Hypertension 44097 (37) 98525 (82) 1.04 0.45 15796 (77) 16799 (82) 0.12 0.94 Anemia 7615 (6) 37210 (31) 0.67 0.20 3596 (18) 4674 (23) 0.13 0.77 Psychosis 1082 (1) 5486 (5) 0.23 0.20 396 (2) 557 (3) 0.05 0.71 Depression 4894 (4) 24721 (21) 0.52 0.20 2571 (13) 3290 (16) 0.10 0.78 Pneumonia 3220 (3) 11612 (10) 0.29 0.28 1102 (5) 1297 (6) 0.04 0.85 HIV 54 (0.05) 142 (0.1) 0.03 0.38 43 (0.2) 46 (0.2) 0.00 0.93 Fracture 1342 (1) 4135 (4) 0.16 0.32 391 (2) 457 (2) 0.02 0.86 RA 1260 (1) 4083 (3) 0.16 0.31 489 (2) 574 (3) 0.03 0.85 Ischemic stroke* 2335 (2) 5937 (5) 0.17 0.39 544 (3) 626 (3) 0.02 0.87 ICH* 1178 (1) 2117 (2) 0.07 0.56 229 (1) 256 (1) 0.01 0.89 MI* 324 (0.3) 1143 (1) 0.09 0.28 165 (1) 170 (1) 0.00 0.97 AKI*
    [Show full text]
  • Antibiotic Classes
    Penicillins Aminoglycosides Generic Brand Name Generic Brand Name Amoxicillin Amoxil, Polymox, Trimox, Wymox Amikacin Amikin Ampicillin Omnipen, Polycillin, Polycillin-N, Gentamicin Garamycin, G-Mycin, Jenamicin Principen, Totacillin, Unasyn Kanamycin Kantrex Bacampicillin Spectrobid Neomycin Mycifradin, Myciguent Carbenicillin Geocillin, Geopen Netilmicin Netromycin Cloxacillin Cloxapen Paromomycin Dicloxacillin Dynapen, Dycill, Pathocil Streptomycin Flucloxacillin Flopen, Floxapen, Staphcillin Tobramycin Nebcin Mezlocillin Mezlin Nafcillin Nafcil, Nallpen, Unipen Quinolones Oxacillin Bactocill, Prostaphlin Generic Brand Name Penicillin G Bicillin L-A, First Generation Crysticillin 300 A.S., Pentids, Flumequine Flubactin Permapen, Pfizerpen, Pfizerpen- Nalidixic acid NegGam, Wintomylon AS, Wycillin Oxolinic acid Uroxin Penicillin V Beepen-VK, Betapen-VK, Piromidic acid Panacid Ledercillin VK, V-Cillin K Pipemidic acid Dolcol Piperacillin Pipracil, Zosyn Rosoxacin Eradacil Pivampicillin Second Generation Pivmecillinam Ciprofloxacin Cipro, Cipro XR, Ciprobay, Ciproxin Ticarcillin Ticar Enoxacin Enroxil, Penetrex Lomefloxacin Maxaquin Monobactams Nadifloxacin Acuatim, Nadoxin, Nadixa Generic Brand Name Norfloxacin Lexinor, Noroxin, Quinabic, Aztreonam Azactam, Cayston Janacin Ofloxacin Floxin, Oxaldin, Tarivid Carbapenems Pefloxacin Peflacine Generic Brand Name Rufloxacin Uroflox Imipenem, Primaxin Third Generation Imipenem/cilastatin Balofloxacin Baloxin Doripenem Doribax Gatifloxacin Tequin, Zymar Meropenem Merrem Grepafloxacin Raxar Ertapenem
    [Show full text]